Zin Myint

Zin Myint is an Associate Professor of Internal Medicine at the University of Kentucky, affiliated with the Markey Cancer Center and its Cancer Research Priority Initiative. His work spans clinical research, translational oncology, and precision medicine in genitourinary cancers.

• Education: Doctor of Medicine (2007) from the University of Medicine, Mandalay, Myanmar; Residency (2016) at Medstar Good Samaritan Hospital/Union Memorial, Baltimore.

Myint’s research focuses on:

• Prostate Cancer (castration-resistant and hormone-sensitive subtypes)
• Renal and Urothelial Carcinomas (clear cell, transitional cell)
• DNA Repair Mechanisms (homologous recombination, genomic instability)
• Clinical Trials (immunotherapy, hormonal therapy, chemotherapy)

Recent trends in his publications emphasize:

• Genomic profiling of androgen indifferent prostate cancer
• Immune checkpoint inhibitors like pembrolizumab
• Targeted therapies (MK-5684, tivozanib, olaparib)
• Biomarker research (BMI impact on survival, DNA repair mutations)

His grants include industry-sponsored studies with Merck Sharp & Dohme and AVEO Pharmaceuticals. He holds the Ambassador William Stamps Farish Faculty Fellowship Fund in Urologic Cancer.